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Abstract
Protective antibodies play a critical role in an effective HIV vaccine; however, eliciting antibodies to block infection by
viruses from diverse genetic subtypes remains a major challenge. As the world’s most populous country, China has been
under the threat of at least three major subtypes of circulating HIV-1 viruses. Understanding the cross reactivity and
specificities of serum antibody responses that mediate broad neutralization of the virus in HIV-1 infected Chinese patients
will provide valuable information for the design of vaccines to prevent HIV-1 transmission in China. Sera from a cohort of
homosexual men, who have been managed by a major HIV clinical center in Beijing, China, were analyzed for cross-sectional
neutralizing activities against pseudotyped viruses expressing Env antigens of the major subtype viruses (AE, BC and B
subtypes) circulating in China. Neutralizing activities in infected patients’ blood were most capable of neutralizing viruses in
the homologous subtype; however, a subset of blood samples was able to achieve broad neutralizing activities across
different subtypes. Such cross neutralizing activity took 1–2 years to develop and CD4 binding site antibodies were critical
components in these blood samples. Our study confirmed the presence of broadly neutralizing sera in China’s HIV-1 patient
population. Understanding the specificity and breadth of these neutralizing activities can guide efforts for the development
of HIV vaccines against major HIV-1 viruses in China.
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Introduction
Infection with HIV-1 in humans leads to the production of
serum antibodies against HIV’s envelope glycoprotein (Env).
Several studies have systematically analyzed HIV-1 positive sera
and discovered that not all HIV-1 infected patient sera achieve
the same potency or breadth of neutralizing activities against
primary HIV-1 viruses and only a fraction of infected sera can
achieve broad neutralization against viruses from different
genetic subtypes [1,2,3,4,5]. Specificities of such protective sera
have been mapped to a limited number of epitopes that
mediate broad and potent serum neutralization [6,7]. These
studies were conducted mainly with several subtypes of viruses
dominating in the United States, United Kingdom, Thailand,
and Africa and many of the subjects were infected via
heterosexual transmission [1,2,3,4,5,8].
However, HIV-1 isolates circulating throughout the world
demonstrate great diversity. In China’s AIDS endemic, there are
three major HIV-1 subtypes: Thai-B, CRF07/08_BC, and
CRF01_AE [9], in addition to other less prevailing subtypes.
Limited studies have described whether sera from people infected
with one of these three subtypes can neutralize viral isolates from
the other two subtypes. If such cross reactivity exists, the antibody
specificities that may be responsible for broad neutralizing
activities are unknown. Such information is valuable to HIV-1
vaccine development in countries such as China where multiple,
equally important circulating viral subtypes have to be covered
during vaccination.
In the current study, sera from a cohort of homosexual men
were analyzed for neutralizing activities against pseudotyped
viruses expressing Env antigens representing the major subtype
viruses circulating in China. Key specificities responsible for the
neutralizing activities have also been mapped in this exploratory
study. Our study confirmed the presence of broadly neutralizing
sera in this patient population and provided a scientific basis to
develop HIV vaccines to achieve broad protection against major
HIV-1 viruses in China. Such information is also useful for
researchers to understand the global pattern of neutralizing
antibodies (NAb) in HIV-1-infected patients, possibly leading to
better control of the AIDS epidemic throughout the world.
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e47548
Methods
HIV-1-infected Patients and Blood Sample Collection
Blood samples were collected from 36 homosexual male patients
from the AIDS Clinic at Youan Hospital, Beijing, China in the
summer of 2009. These patients had various lengths of confirmed
diagnosis of HIV-1 infection.
Ethics Statement
Written informed consent was obtained from all study
participants. Sera and plasma samples were collected from the
study subjects. They were diagnosed with HIV-1 infection but had
not been on regular antiviral treatment prior to the start of the
study. This study was carried out in strict accordance with the
requirements for clinical studies established by the Capital Medical
University, China. The protocol was approved by Youan
Hospital’s Ethics Review Committee.
Isolation of HIV-1 env Genes and env Sequence
Genotyping
RNA was extracted from patient plasma samples using a QIAmp
Viral RNA kit (Qiagen, CA). The envelope gene fragment
covering C2,V5 was amplified with the access RT-PCR system
(Promega, #A1250). Specific primers (Table S1) used to perform
the nested-PCR include outer sense primer TF1 (59 -ATg ggA
TCA AAg CCT AAA gCC ATg TgT-39), outer anti-sense primer
TR1 (59 - gCg CCC ATA gTg CTT CCT gCT -39), inner sense
primer TF2 (59 - ATT Agg CCA gTA gTA TCA ACT CAA -39),
and inner anti-sense primer TR2 (59 - ATA TCT CCT CCT
CCA ggT CTg AA -39). The PCR products were sequenced by
Invitrogen (Shanghai, China). The genotype of each envelope was
determined using the PhyloPlace software from the US NIH HIV
sequence database.
Neutralization Assay
The neutralization assay was performed using a single round of
infection in TZM-bl cells in 96-well plates, as previously described
[10,11]. Pseudoviruses were added at 200 TCID50/well and
incubated with a mAb, HIV-1 patient serum, or a negative control
normal human serum with proper dilutions at 37uC for 60 min.
TZM-bl cells were then seeded at 10,000 cells/well in a final
concentration of 20 mg/mL DEAE dextran. Plates were incubated
at 37uC for 48 hours and developed with luciferase assay reagent
per the manufacturer’s instructions (Promega). Neutralization was
calculated as a percent reduction in luciferase activity in the
presence of mAb or human sera compared to the luciferase activity
induced by the virus in the absence of antibody {12 [RLU + mAb
or immune sera]/[RLU – mAb or immune sera]}6100 [11,12].
The reciprocal neutralizing antibody titers of human sera that
achieved 50% reduction in luciferase activity (IC50) were also
determined.
Peptide Absorption Assay
To examine the potential contribution of V3-specific or
membrane proximal external region (MPER)-specific antibodies
to the neutralizing abilities of patient sera, V3 or MPER peptide
absorption of HIV-1 patient sera was performed prior to
neutralization, as described previously [11]. In this study, the
subtype B consensus V3 peptide (CTRPNNNTRKSITHGPGRA-
FYTTGDIIGDIRQAHC) or Group M consensus MPER pep-
tides were used. The MPER peptides include six peptides of 15-
mer sequences with 11 amino acids overlap covering both 2F5 and
4E10 epitopes spanning the 35 amino acid MPER region
(LIEESQNQQEKNEQELLALDKWASLWNWFDITNWL).
One peptide (V3) or a mixture of six peptides (MPER) were added
at a final concentration of 30 mg/ml to serially diluted serum
samples and incubated at 37uC for 60 min. Then HIV-1
pseudovirus was added to the sera-peptide mixture for 37uC for
60 min. TZM-bl cells were then seeded at 10,000 cells/well in
a final concentration of 20 mg/ml DEAE-dextran. Plates were
incubated at 37uC for 48 hours before being developed with the
luciferase assay reagent according to the manufacturer’s instruc-
tions (Promega). The percent reduction in neutralization was
calculated as follows: [1 - (NAb titer in the presence of peptide)/
(NAb titer in the absence of peptide)].
Virus Capture Competition Assay
In order to analyze the antibody specificity of patient sera, HIV-
1 viral capture competition assays were performed against known
HIV-1 neutralizing monoclonal antibodies, including CD4bs-
specific b12, VRC01 and VRC03 [7], and glycan-specific 2G12
and quaternary epitope-specific PG9 [13], as previously described
[11]. Pseudotyped virions in this assay express both HIV-1 JR-FL
Env and vesicular stomatitis virus (VSV) G protein. The VSV G
protein mediates the entry of virions into the target cell line TZM-
bl irrespective of any neutralizing activity against the HIV
envelope present in the sera, thus providing a sensitive readout
of captured virus as previously described [14]. The capture of
pseudovirions by HIV-1 mAbs will be blocked if there is
a competing antibody in the patient sera. Specifically, microwells
were coated with individual mAbs (5 mg/ml) overnight and were
then washed and blocked with 3% bovine serum albumin in PBS.
Graded dilutions of patient sera were added to the virus, and the
virus-serum mixtures were then added to mAb-coated ELISA
wells for 3 hours, followed by washing with PBS. TZM-bl cells
were overlaid, and 48 hours later, infection was measured by
assaying luciferase activity. The reciprocal serum dilution that
inhibited mAb-mediated virus capture by 50% was recorded.
Statistical Analysis
Fisher’s exact test was used to determine the statistical
differences in NAb among patient sera collected at various time
points and their subtype specificities. Correlations between
neutralization breadth and V3 peptide absorption or between
neutralization breadth and antibody titers competing with
neutralizing mAb IgG1 b12 were analyzed using Spearman’s
rank correlation.
Results
Features of the HIV-1 Infected Cohort
Blood samples were collected from 36 male homosexual patients
with a well-documented history of HIV-1 infection and most have
the dates of their first diagnosis of HIV infection. Samples were
collected during one of the patients’ regular clinic visits as a part of
routine monitoring of their disease condition. The average age of
this group was 30 years with an average blood CD4+ T cell count
of 502 (Table S2). The period of time from diagnosis to sample
collection ranged from 0.2–4.4 years, with 16 patients having less
than a 1-year history of infection, 10 between 1–2 years’ history,
and four with longer than 2 years’ history. Six patients could not
provide reliable information on the exact length of infection.
Identification of Viral Subtypes in Infected Plasma
The C2-V5 region of the HIV-1 env gene was amplified from
patient plasma by reverse transcription (RT) and nested-poly-
merase chain reaction (PCR), using primers described in Table S1,
Neutralizing Activities against China’s HIV
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and the gene products were sequenced. These env gene sequences
were analyzed for HIV-1 subtypes based on the NIH HIV
sequence database. The majority of env gene sequences isolated
from this group of patients belonged to subtypes B/ThaiB, BC,
and AE, which are the three major circulating HIV-1 subtypes in
China (Fig. S1 and Table S3). Subtypes for env gene products from
two patients in this cohort were unidentifiable and, therefore, were
not included for NAb analysis.
Neutralizing Activities in Infected Patients’ Sera
NAb analysis was conducted against pseudotyped virus infection
in TZM-bl cells (Fig. 1). A panel of pseudotyped viruses expressing
44 primary HIV-1 Env antigens was included in this study: 14
from subtype B viruses, 11 from subtype BC, 7 from subtype C,
and 12 from subtype AE. Two pseudotyped viruses expressing
either an Env antigen from a T-cell line adapted (TCLA) virus
(NL4-3) or an Env from a sensitive primary virus (SF162) were
included as controls. The breadth and potency of such activities
varied widely among this cohort. Given the large differences in
NAb titers, a summary of neutralizing activities was compiled by
using the same serum dilution at 1:20. The percent inhibition at
this serum dilution was reported to indicate the relative strength of
such activities when inhibition less than 50% was considered
negative in the current assay (Fig. 1).
Among 34 serum samples where env gene subtypes were
mapped, 25 showed NAb responses against both sensitive viruses
(SF162 and NL4-3), three (NJ016, NJ020, and NJ033) could only
neutralize one virus, and the remaining six samples (NJ024,
NJ022, NJ015, NJ038, NJ032, and NJ021) could not neutralize
either virus. Among these nine samples that could not neutralize
either sensitive virus, all, except one (NJ016), had a history of
infection for less than 1-year, indicating that sera from patients
with a shorter time period after infection were unable to generate
effective neutralizing activities. In support of this view, the only
two serum samples (NJ015 and NJ021) that could not neutralize
any viruses expressing primary Env in our analysis were among
these nine samples. The remaining seven samples had neutralizing
Figure 1. NAb activities against HIV-1 pseudotyped viruses. Neutralization was shown as the percent inhibition of virus infection at 1:20
dilution of the patient sera or using 10 mg/ml of monoclonal antibodies (b12, 2G12, and 4E10). ‘‘2‘‘ indicates that percent of neutralization was below
50%. Percent of neutralization between 50–75% or greater than 75% are highlighted in yellow or red, respectively. The HIV-1 pseudotyped viruses
used for neutralization assays are shown in the second row from top from ‘‘NL4-3’’ to ‘‘CM235.c11’’ with subtype indicated above the virus panel.
‘‘MuLV’’ is the murine leukemia virus used as negative control for neutralization assays. ‘‘NJ0XX’’s in the far left column indicates individual patient
serum samples; patient HIV subtypes are indicated above each group of samples. Known neutralizing monoclonal antibodies, IgG1 b12, 2G12 and
4E10, served as positive controls for neutralization assays.
doi:10.1371/journal.pone.0047548.g001
Neutralizing Activities against China’s HIV
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activities against no more than 1–3 primary Env pseudotyped
viruses.
For the 25 patient sera samples that were able to neutralize both
of the sensitive viruses, only two (NJ006 and NJ035), both from
patients with less than 1-year infection, could not neutralize any
other primary Env pseudotyped viruses, suggesting that once NAb
are elicited, sera can neutralize not just the sensitive viruses, but
also additional primary Env viruses.
As reported in the past, these serum samples showed preferred
neutralization against viruses from the autologous subtype (Fig. 1).
By using the high percentage inhibition (75–100%) as a more
reliable measurement on the strength of neutralizing activities (red
boxes in Fig. 1), there were nine ‘‘hits’’ in subtype B sera against
subtype B Env pseudotyped viruses, none against subtype BC, one
hit against subtype C, and two hits against subtype AE Env. Sera
from subtype BC had a combined nine ‘‘hits’’ against subtypes BC
and C, three against subtype B, and none against subtype AE Env.
Finally, sera from patients infected with subtype AE viruses, had
a strikingly high level of ‘‘hits’’ (N= 10) against the subtype AE
Env, but only two against subtype B, and none against subtypes C
and BC Env.
When a more quantitative analysis was conducted by combining
all positive neutralizing activities together (both red and yellow
(50–74% inhibition) boxes, serum samples from subtype B patients
had the highest percentage of neutralization against subtype B
viruses, which was significantly higher than the subtypes BC
(p= 0.002) and AE (p= 0.015) (Fig. 2A). Subtype BC patient sera
neutralized more subtype C than the subtypes B, BC, or AE
(p = 0.04, p = 0.003, and p= 0.0001, respectively) (Fig. 2B). Serum
samples from subtype AE patients neutralized more subtype AE
viruses than subtypes B, C, and BC (p= 0.0034, p= 0.004, and
p= 0.014 respectively) (Fig. 2C). Our data demonstrated that, in
general, HIV-1-infected patient sera tend to have the best
neutralizing activities against viruses from the autogolous subtype
but there is a low frequency of cross-subtype neutralizing activities,
more likely with sera from patients infected with subtypes B and
BC viruses.
A subset of patient sera showed quite broad neutralizing
activities (Fig. 1). Among 10 patients infected with subtype B
viruses, four (40%) could neutralize viruses from 3–4 subtypes.
Among 14 patients infected with subtype BC viruses, seven sera
(50%) were able to neutralize viruses from 3–4 subtypes. Among
10 patients infected with subtype AE viruses, four (40%) were able
to neutralize 3–4 subtypes. However, even among these cross-
subtype neutralizing serum samples, only five samples (NJ019,
NJ025, NJ030, NJ012, NJ028), representing 15% of total serum
samples tested, could neutralize more than 50% of this 44-virus
panel across all four subtypes.
Delayed Emergence of Broadly NAb Responses
Since many serum samples included in the current study did not
show broad NAb responses until later in infection, it was
interesting to examine whether a longer period of infection in
the host may be needed in order to elicit broad NAb responses.
Using subtype B virus-infected patient sera as an example, Fig. 3
(A–D) shows that NAb titers increased after one year’s infection
against two sensitive viruses (SF162 and NL4-3); similar results
were found using sera that showed positive neutralizing activities.
When all serum samples were included, sera with positive
neutralizing activities against the two sensitive viruses increased
from less than 50% of the total samples for those with ,1 year’s
infection to close to 100% for those with .2 years’ infection
(Fig. 3E). The same pattern was observed against 44 primary Env
pseudotyped viruses (Fig. 3F), most of which were more resistant
Figure 2. Subtype specificity of NAb responses identified in
HIV-1 infected patients’ sera. Neutralization against pseudotyped
viruses expressing primary Env from subtypes B, BC, C, and AE isolates
were tested. Percentage of neutralization by patients’ sera (at 1:20
dilution) infected with one of three viral subtypes (B, BC, and AE as
shown in panels A, B, and C, respectively) were calculated. The
significant differences (p,0.05) of neutralizing activities between
different groups of patient sera are indicated.
doi:10.1371/journal.pone.0047548.g002
Neutralizing Activities against China’s HIV
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Figure 3. Improvement of NAb responses after one year of HIV-1 infection. Panels A, B, C and D represent the percent (%) of neutralization
at 1:20 serum dilution against two sensitive subtype B viruses (SF162 and NL4-3), within 1 year, between 1–2 years, longer than 2 years of infection, or
time of initial infection unknown. Panels E and F represent the percentage of HIV-1 infected patient sera that showed positive NAb responses (using
IC50 at 1:20 serum dilution as the cut-off) based on length of infection (,1 year, 1–2 years, and .2 years). Panel A shows neutralizing activities
against two sensitive viruses (SF162 and NL4-3) and panel B against 44 pseudotyped viruses expressing primary Env antigens (see Fig. 1). The levels of
statistical difference between patient sera with different lengths of infection are indicated, which were determined by Fisher exact test.
doi:10.1371/journal.pone.0047548.g003
Neutralizing Activities against China’s HIV
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viruses. On average, less than 5% of the neutralizing events against
the primary Env viruses were observed with sera from patients
infected ,1 year, but this rate increased to close to 20% with 1–2
years’ infection, and to more than 30% after two years’ infection
(Fig. 3F).
Figure 4. Analysis of possible correlations between neutralization breadth in HIV-1 patient sera and selected known neutralizing
epitopes V3 and CD4bs. A. Analysis on the relationship between the reduction of neutralizing activities after V3 peptide absorption in patient sera
and the breadth of neutralization with the same patient sera. Percent reduction of neutralizing activities against pseudotyped SF162 was tested with
individual patient serum (1:20 dilution) after absorption with the subtype B consensus V3 peptide. The alignment of subtype B consensus (Cons-B)
and SF162 V3 sequence is shown. The number of primary Env pseudotyped viruses (total 44) neutralized by each individual patient serum were
calculated as shown in Fig. 1. Correlations and significance were determined using the Spearman method. B. The relationship between antibody titers
to compete against neutralizing mAb b12 and the breadth of neutralization (number of viruses being neutralized) in the same patient sera was
analyzed. Correlations and significance were determined using the Spearman method.
doi:10.1371/journal.pone.0047548.g004
Neutralizing Activities against China’s HIV
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Neutralizing Antibody Specificity Analysis
In order to further understand the specificity of anti-Env
antibody responses that may be responsible for the breadth of NAb
against primary HIV-1 viruses in this cohort of HIV-1-infected
patients, two types of assays were conducted. In the first assay,
serum samples were treated with HIV-1 subtype B consensus V3
peptide before the same neutralization study was conducted
against SF162, which can be neutralized by majority of the patient
sera in this study. Decreases in NAb responses upon the treatment
of this V3 peptide were observed although a significant number of
sera only had a moderate drop (20–40%) with V3 peptide
treatment (Fig. 4A). An overall inverse-correlation was observed
between the reduction of neutralizing activity upon treatment with
Figure 5. MPER peptide inhibition of neutralizing activities of Env-specific mAbs and HIV-1 patient sera. A: MPER inhibition of NAb
activities of mAbs (b12 against CD4bs, 2F5 and 4E10 against MPER) as control; B: MPER inhibition of NAb activities of patient sera with relative broad
NAb activities (NJ009, NJ010, NJ012, NJ019, NJ025, NJ028, NJ030, NJ034, and NJ040).
doi:10.1371/journal.pone.0047548.g005
Neutralizing Activities against China’s HIV
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V3 peptide and the breadth of NAb responses (r =20.409,
p = 0.022). These results suggested that patient sera with broader
neutralizing activities were less V3-dependent while those with
narrower neutralizing activities were more V3-dependent against
SF162 tested in this study.
Nine serum samples with relative broad NAb activities were
further treated with HIV-1 Group M consensus MPER peptides
(six peptide pool spanning both 2F5 and 4E10 epitopes) before the
same neutralization study was conducted against SF162. De-
creases in NAb activities upon treatment of MPER peptides were
only observed in patient NJ040 and not in the other eight sera
samples (NJ009, NJ010, NJ012, NJ019, NJ025, NJ025, NJ028,
NJ030, and NJ034) (Fig. 5B). To control the MPER absorption
assays, CD4bs-specific mAb b12 and MPER-specific mAbs 2F5
and 4E10 were also treated with MPER peptides before
neutralization. As expected, MPER peptides could inhibit the
NAb activities of MPER-specific mAbs 2F5 and 4E10 but could
not inhibit the NAb activity of gp120-specific mAb b12 (Fig. 5A).
These results suggest that patient sera with broader neutralizing
activities are not MPER-dependent.
The next study examined the antibody components in patients’
sera that can compete against b12, a well-known CD4 binding site
(CD4bs) neutralizing monoclonal antibody. Here, a significant
correlation was observed between titers of b12-competing
antibody responses and the number of primary viruses being
neutralized (p = 0.005, r = 0.533) (Fig. 4B).
To further support this finding, four broadly neutralizing sera
from the current patient cohort were analyzed for the presence of
antibodies that may compete against two newly discovered broadly
neutralizing human mAbs, VRC01 and VRC03, which also target
the CD4bs (Table 1). Two sera infected with subtype B viruses,
NJ019 and NJ025, showed broad neutralizing activities against
HIV-1 viruses from different subtypes (Table 1). Both showed
positive competing antibodies against VRC01 and VRC03
although their relative titers were much lower than the b12-
competing antibodies (Table 1). NJ040, a serum infected with
subtype AE virus, had only low level VRC03-competing
antibodies, and the fourth serum, NJ004, infected with subtype
C, did not have detectable levels of antibodies competing against
either VRC01 or VRC03. Interestingly, both NJ040 and NJ004
sera had low levels of b12-competing antibody responses. In
contrast, four serum samples (one from subtype B, two from
subtype C, and one from subtype AE), which had very poor
neutralization against the primary viruses and did not have
significant b12-competing antibodies, also failed to show the
presence of competing antibodies against both VRC01 and
VRC03. Although this analysis was conducted on only a few
samples, the results demonstrate the presence of VRC01- and
VRC03-competing antibodies in broadly neutralizing sera and,
more likely, in sera rich in b12-competing antibodies.
To further examine the specificity of patient sera with relative
broad NAb activities, we conducted mAb competition assays
against glycan-specific mAb 2G12 and quaternary epitope-specific
mAb PG9 (Table 2). Among nine patient sera with relative broad
NAb, only patient NJ019 had detectable low titers of antibodies
competing against mAbs 2G12 and/or PG9. This implied that
2G12-like or PG9-like antibodies were not in significant amounts
Table 1. CD4bs mAb competition antibody titers.
Patient serum No. of positive NAb against primary viruses gp120 CD4bs specific mAb
b12 VRC01 VRC03
Narrow NAb*
NJ015 0 – – –
NJ035 0 – – –
NJ024 1 44 – –
NJ033 1 – – –
Broad NAb*
NJ040 15 20 – 29
NJ004 17 160 – –
NJ019 22 368 20 116
NJ025 24 2502 156 152
‘‘2‘‘ indicates that the antibody titer is below detection level at 1:20 serum dilution.
*significant difference for CD4bs mAb competition antibodies between patient sera with Narrow or Broad NAb activities (p = 0.0014 by Fisher exact test).
doi:10.1371/journal.pone.0047548.t001
Table 2. Antibody titers competing against Env-specific mAbs 2G12 and PG9 in patient sera with relative broad NAb activities.*
Env-specific mAbs Subject ID
NJ009 NJ010 NJ012 NJ019 NJ025 NJ028 NJ030 NJ034 NJ040
2G12 – – – 35 – – – – –
PG9 – – – 27 – – – – –
*The mAb 2G12 competition assays were conducted against SF162 while the PG9 competition assays were performed against NL4-3.
‘‘2‘‘ indicates the competition antibody titers were below the detection level (1:20).
doi:10.1371/journal.pone.0047548.t002
Neutralizing Activities against China’s HIV
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in this set of patient sera when compared to CD4bs-mAb-like
antibodies.
Using the same virus capture competition assay, two mAbs
recognizing glycosylated Env antigens and quarternary structure
(2G12 and PG9) were tested to compete against HIV-infected sera
(Table 2). Except for one serum, which showed low titers against
both mAbs, most of other broadly neutralizing antibodies could
not compete against these two mAbs.
Discussion
In this study, we reported neutralizing activities in a group of
HIV-1-infected homosexual male patients from Beijing, China.
Like many other countries, China has not escaped the AIDS
endemic that has occurred over the past two decades. While
initially HIV-1 infections have been mainly observed in injection
drug users in certain border provinces, the latest data suggest an
increase in HIV-1 infections in urban areas through sexual
transmission [9,15], including an alarming rate of homosexual
transmission [16,17,18,19]. Following these new epidemiological
trends and gaining a better understanding of immune responses
among people infected with HIV-1 in China will provide useful
information on the dynamics and ultimate control of the AIDS
epidemic in China. At the same time, we need to be mindful on
the recent RV144 trial data [20], which showed that NAb
response was not one of the immune correlates for protection.
More vaccination studies are needed to fully define any protective
roles that NAb may play for HIV-1 vaccines.
It is well-documented in the literature that the genetic makeup
of HIV-1 in China is quite complex due to the way various viral
subtypes infect different risk groups within the population. Three
main subtypes have dominated HIV-1 infections in China
including CRF07/08_BC (BC), subtype B’ (B’), and CRF01_AE
(AE). Previous studies have suggested that each of these subtypes
was associated with a particular mode of transmission [21,22]:
intravenous drug use with BC viruses, commercial blood and
plasma donation with B’ viruses, and sexual transmission with AE
viruses. Furthermore, it was also suggested that AE viruses were
found more in those infected via homosexual transmission [21].
However, in our current study, we have identified all three major
subtypes in the homosexual male population indicating different
subtypes of viruses have reached major urban areas, including
Beijing. Given the relatively small size of this cohort, the exact
rates of infection by each of the three major subtypes were not
determined.
Co-circulation of multiple subtypes of HIV-1 is a challenge to
vaccine development in China. Furthermore, China offers
a unique geographic model to examine cross-neutralizing antibody
activities against well-defined subtypes in the same region. While
early studies did not reach a consensus on the presence of subtype-
specific humoral responses in HIV-1-infected people
[23,24,25,26], recent reports on the analysis of patient serum
antibodies in China support the preferred neutralization of viruses
of the autologous subtype [27,28,29]. Data in the current report
further confirm that HIV-1-infected patient sera are, indeed, more
capable of neutralizing viruses in the same subtype compared to
viruses from other subtypes. Even for those sera with cross-subtype
neutralizing activities, they exhibited either a higher titer or
a higher frequency when it came to neutralizing viruses from the
autologous subtype.
However, our data also suggest that such subtype specificity is
not absolute. Many sera showed various degrees of cross-
neutralizing activities against viruses from other subtypes. Between
40–50% of the tested sera were able to neutralize viruses in more
than three subtypes but the real broadly neutralizing sera, which
could neutralize more than 50% of the virus panel, represented
only 15% of the sera; results from this study also showed that it will
take more than 1–2 years’ time to develop such breadth. Previous
studies on HIV-infected patients in China either did not pay
particular attention to identifying broadly neutralizing sera
[27,28,29] or only used pooled sera to determine those that
greatly reduced the sensitivity to detect such high quality
neutralizing sera [17]. The finding of such naturally occurring
broad neutralizing sera made it feasible to elicit similar broad NAb
through vaccination.
It is particularly critical to understand the specificity of antibody
responses responsible for the induction of broadly NAb against
viruses in all three subtypes. Our data suggest that there are
antibodies against more than one neutralizing epitope present in
these sera and CD4bs antibodies may play a critical role in the
breadth of neutralizing activities. Our results did not identify
antibodies similar to either 2G12 or PG9. Peptide absorption using
a MPER peptide was not able to reduce the NAb identified in our
HIV patient sera. However, the current study is only exploratory
and detailed studies are needed to examine neutralizing activity
against pseudotyped viruses with selected mutations on those
existing Env to further map out critical sites involved in
neutralizing viruses in both autologous and heterologous subtypes;
such information will guide the design of Env vaccine formulations
to elicit broadly neutralizing activities.
Our data also point to a major challenge in eliciting NAb
responses, i.e. the lengthy period required to detect such antibody
responses in naturally-infected hosts. We realize the limitation of
the cross-sectional nature of our data as we did not follow these
patients over time with multiple sampling time points. It is not
clear whether such a long process is needed to let the viruses evolve
in order to allow for the development antibodies against a more
diverse viral population, or whether a long B-cell maturation
process is needed to produce high-quality antibody responses
against the same key epitopes. In the former situation, future
vaccines will need to be based on ‘‘polyvalent’ principles to expand
the breadth of immunogens. In the latter scenario, more effective
immunization approaches may be needed, such as the use of
adjuvants to selectively accelerate the necessary steps for the
production of high quality antibodies. Both approaches can be
tested in future vaccine studies to determine if similar cross-
subtype antibody responses can be reproduced.
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